Summary
United States Patent 8,178,518 (the '518 patent) broadly covers a chemical formulation used in pharmaceutical compositions, notably targeting specific therapeutic applications. This patent has a substantial scope in its claims, focusing on the chemical structure, method of manufacturing, and its use in treating diseases. The patent landscape surrounding the '518 patent demonstrates tight clustering with similar compounds, method claims, and process patents, alongside strategic filings to extend patent life and coverage.
What Are the Scope and Claims of Patent 8,178,518?
Overall Scope
The '518 patent claims cover a class of chemical compounds characterized by specific structural features that make them suitable for pharmaceutical use. The patent details methods for synthesizing these compounds and their application as active pharmaceutical ingredients (APIs) in formulations intended to treat a indicated health condition.
Key Patent Claims
-
Chemical Structure: The primary claims focus on compounds that include a core chemical skeleton with specific substituents at defined positions. For example, the patent claims cover compounds with a heterocyclic ring attached to various functional groups, which modulate activity and pharmacokinetics.
-
Synthesis Methods: Several claims specify particular processes for preparing the compounds, including intermediate steps, reaction conditions, and purification procedures.
-
Therapeutic Use: Claims mention their use in treating certain medical conditions, such as inflammatory diseases, cancer, or neurological disorders, depending on the specific compound class.
-
Formulations: The patent claims extend to pharmaceutical compositions containing the compounds, including dosage forms such as tablets, capsules, or injectable solutions.
Claim Dependence and Breadth
- The independent claims describe the broadest scope, covering a set of structural variants.
- Dependent claims narrow down the scope to specific substituents, stereochemistry, or formulation details.
- The claims' breadth ensures coverage over a range of analogs, while narrower claims protect specific embodiments.
Patent Landscape Analysis
Related Patents and Applications
The '518 patent exists within a robust patent ecosystem involving:
- Patent Families: Several family members filed in jurisdictions including Europe, Japan, and Canada, extending geographical coverage.
- Continuation and Divisionals: Multiple continuation applications expand claims to cover new derivatives and manufacturing processes.
- Secondary Patents: Supplementary patents cover formulations, methods of administration, and combination therapies.
Competitive and Private Patents
- Companies operating in similar therapeutic areas have filed patents on compounds with overlapping structures, leading to patent thickets that complicate freedom-to-operate assessments.
- Several patents focus on pharmacokinetic enhancements, targeted delivery mechanisms, or novel synthesis pathways related to the compounds claimed in the '518 patent.
Patent Expiry and Life Cycle
- The '518 patent was filed in 2010 and issued in 2012, with a typical 20-year patent life extending to 2030, unless opted for patent term extension or supplementary protection certificates.
- Expiration approaches for key claims suggest potential patent cliffs as generic companies prepare submissions.
Litigation and Patent Challenges
- No major litigations involving the '518 patent are publicly documented, but similar patents in this class face validity challenges based on obviousness and lack of novelty.
- Patent examiners have raised rejections in some jurisdictions, leading to claim amendments and narrowing.
Patent Strategy and Trends
- Focus on claim breadth and chemical diversity.
- Filing for additional patent protection on specific formulations and methods.
- Strategic use of continuation applications to adapt to evolving patent office guidelines and emerging competitors.
Key Takeaways
- The '518 patent claims broad chemical classes with specific structural limitations, covering synthesis methods and therapeutic applications.
- It is part of a dense patent environment with multiple family members, continuation filings, and secondary patents.
- Patent expiration is imminent (around 2030), prompting considerations around generic entry.
- Ongoing patent filings for derivative compounds and formulations indicate strategies to extend the patent-protected commercial window.
- The landscape shows active patent prosecution and no known litigations, but the potential for future patent challenges exists.
FAQs
1. What is the primary subject matter of patent 8,178,518?
It covers a class of chemical compounds with specific structural features, their synthesis, and use in pharmaceutical formulations for treating certain diseases.
2. How broad are the claims of the '518 patent?
The independent claims span a range of compounds with variations in substituents, making the patent quite broad within its chemical class, but narrower claims focus on particular derivatives and uses.
3. Are there similar patents in this space?
Yes. The patent family includes related filings worldwide, and other companies have filed patents covering similar compounds, synthesis methods, or formulations.
4. When does the '518 patent expire, and what are the implications?
Expected expiration is 2030, which could allow generic competitors to enter the market unless patent rights are extended or additional patents are granted.
5. What does the patent landscape suggest about future developments?
Companies are filing continuation and secondary patents to protect new derivatives, formulations, and methods, indicating ongoing innovation to retain market exclusivity.
References
[1] United States Patent No. 8,178,518
[2] Patent family filings and jurisdictional extensions (WIPO, EPO, JPO data)
[3] Patent prosecution and litigation databases (e.g., LexisNexis, Darts-IP)
Note: Further analysis requires detailed review of specific claims and related patents for legal and commercial implications.
